Uniphar plc

AIM:UPR Stock Report

Market Cap: UK£475.3m

Uniphar Valuation

Is UPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UPR (£1.76) is trading above our estimate of fair value (£1.47)

Significantly Below Fair Value: UPR is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UPR?

Key metric: As UPR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UPR. This is calculated by dividing UPR's market cap by their current earnings.
What is UPR's PE Ratio?
PE Ratio12.7x
Earnings€45.17m
Market Cap€571.97m

Price to Earnings Ratio vs Peers

How does UPR's PE Ratio compare to its peers?

The above table shows the PE ratio for UPR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.3x
CVSG CVS Group
22.8x15.5%UK£596.9m
SPI Spire Healthcare Group
31.3x26.9%UK£885.2m
AMS Advanced Medical Solutions Group
41x23.0%UK£456.3m
IDHC Integrated Diagnostics Holdings
14x23.7%US$229.9m
UPR Uniphar
12.7x9.4%UK£572.0m

Price-To-Earnings vs Peers: UPR is good value based on its Price-To-Earnings Ratio (12.7x) compared to the peer average (27.3x).

Price to Earnings Ratio vs Industry

How does UPR's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
UPR 12.7xIndustry Avg. 18.7xNo. of Companies10PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UPR is good value based on its Price-To-Earnings Ratio (12.7x) compared to the European Healthcare industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is UPR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UPR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.7x
Fair PE Ratio23x

Price-To-Earnings vs Fair Ratio: UPR is good value based on its Price-To-Earnings Ratio (12.7x) compared to the estimated Fair Price-To-Earnings Ratio (23x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UPR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£1.76
UK£3.79
+115.4%
7.1%UK£4.19UK£3.35n/a5
Nov ’25UK£1.90
UK£3.79
+100.0%
7.1%UK£4.19UK£3.35n/a5
Oct ’25UK£2.14
UK£3.81
+77.9%
7.1%UK£4.21UK£3.37n/a5
Sep ’25UK£2.29
UK£3.72
+62.6%
8.6%UK£4.21UK£3.37n/a5
Aug ’25UK£2.23
UK£3.72
+67.0%
8.6%UK£4.21UK£3.37n/a5
Jul ’25UK£2.10
UK£3.79
+80.6%
8.6%UK£4.29UK£3.43n/a5
Jun ’25UK£2.25
UK£3.79
+68.5%
8.6%UK£4.29UK£3.43n/a5
May ’25UK£2.18
UK£3.64
+66.8%
12.1%UK£4.28UK£2.91n/a6
Apr ’25UK£2.25
UK£3.70
+64.5%
11.9%UK£4.28UK£2.91n/a7
Mar ’25UK£2.36
UK£3.70
+56.9%
11.9%UK£4.28UK£2.91n/a7
Feb ’25UK£2.47
UK£3.76
+52.4%
12.2%UK£4.29UK£2.92n/a6
Jan ’25UK£2.24
UK£3.76
+68.1%
12.2%UK£4.29UK£2.92n/a6
Dec ’24UK£1.85
UK£3.68
+99.0%
14.2%UK£4.34UK£2.95n/a7
Nov ’24UK£1.95
UK£3.68
+89.3%
14.2%UK£4.34UK£2.95UK£1.907
Oct ’24UK£1.99
UK£3.64
+82.9%
13.6%UK£4.32UK£2.94UK£2.148
Sep ’24UK£2.35
UK£3.71
+58.0%
11.5%UK£4.33UK£2.95UK£2.298
Aug ’24UK£2.55
UK£3.64
+42.8%
10.9%UK£4.28UK£2.91UK£2.238
Jul ’24UK£2.72
UK£3.69
+35.6%
10.9%UK£4.34UK£2.95UK£2.108
Jun ’24UK£2.78
UK£3.69
+32.7%
10.9%UK£4.34UK£2.95UK£2.258
May ’24UK£2.62
UK£3.78
+44.3%
6.3%UK£4.07UK£3.54UK£2.186
Apr ’24UK£2.72
UK£3.85
+41.8%
5.7%UK£4.07UK£3.54UK£2.256
Mar ’24UK£2.90
UK£3.93
+35.7%
4.8%UK£4.09UK£3.56UK£2.365
Feb ’24UK£3.08
UK£3.96
+28.8%
6.2%UK£4.28UK£3.53UK£2.475
Jan ’24UK£2.68
UK£3.96
+48.0%
4.6%UK£4.24UK£3.67UK£2.245
Dec ’23UK£3.02
UK£3.96
+31.0%
4.6%UK£4.24UK£3.67UK£1.855
Nov ’23UK£2.95
UK£3.99
+35.2%
3.9%UK£4.25UK£3.77UK£1.955

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.47

7D

3.3%

1Y

-18.2%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$401.70

7D

0.3%

1Y

-15.8%

Enovis

US$2.6b

Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

0I1B

US$46.90

7D

2.6%

1Y

-7.2%